Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases

HPB

Volumn 18, Issue 6, 2016, Pages 485-493

  Khoo, Emily ^a   O'Neill, Stephen ^a   Brown, Ewan ^a   Wigmore, Stephen J ^a   Harrison, Ewen M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL LIVER METASTASIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; ADULT; AGED; COLORECTAL TUMOR; DISEASE EXACERBATION; FEMALE; LIVER RESECTION; LIVER TUMOR; MALE; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; RISK FACTOR; SECONDARY; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84974827678     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1016/j.hpb.2016.03.001     Document Type: Review

References (43)

1. J. Leporrier, J. Maurel, L. Chiche, S. Bara, P. Segol, and G. Launoy A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer Br J Surg 93 2006 465 474
2. P.C. Simmonds, J.N. Primrose, J.L. Colquitt, O.J. Garden, G.J. Poston, and M. Rees Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies Br J Cancer 94 2006 982 999
3. J. Scheele, R. Stangl, and A. Altendorf-Hofmann Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history Br J Surg 77 1990 1241 1246
4. M.C. de Jong, C. Pulitano, D. Ribero, J. Strub, G. Mentha, R.D. Schulick, and et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients Ann Surg 250 2009 440 448
5. G. Portier, D. Elias, O. Bouche, P. Rougier, J.F. Bosset, J. Saric, and et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial J Clin Oncol 24 2006 4976 4982
6. NICE. Colorectal cancer: The diagnosis and management of colorectal cancer. Available from: https://www.nice.org.uk/guidance/cg131/resources/guidance-colorectal-cancer-pdf.
7. NCCN. Colon cancer guidelines v. 3 2012; (28/9/2014). Available from: http://www.nccn.org/professionals/physician-gls/pdf/colorectal-screening.pdf.
8. S.R. Alberts Evolving role of chemotherapy in resected liver metastases J Clin Oncol - Off J Am Soc Clin Oncol 24 2006 4952 4953
9. G. Nigri, N. Petrucciani, F. Ferla, M. La Torre, P. Aurello, and G. Ramacciato Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies Surg - J R Coll Surg Edinb Irel 13 2015 83 90
10. D. Ciliberto, U. Prati, L. Roveda, V. Barbieri, N. Staropoli, A. Abbruzzese, and et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials Oncol Rep 27 2012 1849 1856
11. H.I. Hurwitz, N.C. Tebbutt, F. Kabbinavar, B.J. Giantonio, Z.Z. Guan, L. Mitchell, and et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials Oncology 18 2013 1004 1012
12. N.P. Tang, H. Li, Y.L. Qiu, G.M. Zhou, Y. Wang, J. Ma, and et al. Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials Tumour Biol - J Int Soc Oncodevelopmental Biol Med 35 2014 10409 10418
13. G. Folprecht, S. Hamann, K. Schutte, T. Trarbach, J. Stoehlmacher-Williams, and G. Ehninger Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer BMC Cancer 14 2014 521
14. L. Rubbia-Brandt, E. Giostra, C. Brezault, A.D. Roth, A. Andres, V. Audard, and et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery Ann Oncol 18 2007 299 304
15. L. Vigano, L. Capussotti, G. De Rosa, W.O. De Saussure, G. Mentha, and L. Rubbia-Brandt Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival Ann Surg 258 2013 731 740 discussion 41-2
16. A.Z. Khan, G. Morris-Stiff, and M. Makuuchi Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases J Hepato Biliary Pancreatic Surg 16 2009 137 144
17. P.S. Wolf, J.O. Park, F. Bao, P.J. Allen, R.P. DeMatteo, Y. Fong, and et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience J Am Coll Surg 216 2013 41 49
18. F. Makowiec, S. Mohrle, H. Neeff, O. Drognitz, G. Illerhaus, O.G. Opitz, and et al. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases J Gastrointest Surg - Off J Soc Surg Alimentary Tract 15 2011 153 164
19. P. Ryan, S. Nanji, A. Pollett, M. Moore, C.A. Moulton, S. Gallinger, and et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy Am J Surg Pathol 34 2010 784 791
20. F.G. Fernandez, J. Ritter, J.W. Goodwin, D.C. Linehan, W.G. Hawkins, and S.M. Strasberg Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases J Am Coll Surg 200 2005 845 853
21. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269 w64
22. M. Ychou, W. Hohenberger, S. Thezenas, M. Navarro, J. Maurel, C. Bokemeyer, and et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer Ann Oncol - Off J Eur Soc Med Oncol ESMO 20 2009 1964 1970
23. B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston, P.M. Schlag, P. Rougier, and et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial Lancet Oncol 14 2013 1208 1215
24. J. Primrose, S. Falk, M. Finch-Jones, J. Valle, D. O'Reilly, A. Siriwardena, and et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial Lancet Oncol 15 2014 601 611
25. J. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] Cochrane Collab 2011 [Internet]. Available from: www.cochrane-handbook.org
26. A. Saiura, J. Yamamoto, K. Hasegawa, M. Oba, T. Takayama, S. Miyagawa, and et al. A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study Drug Discov Ther 8 2014 48 56
27. N.E. Kemeny, W.R. Jarnagin, M. Capanu, Y. Fong, A.N. Gewirtz, R.P. Dematteo, and et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer J Clin Oncol 29 2011 884 889
28. M.M. Kemeny, S. Adak, B. Gray, J.S. Macdonald, T. Smith, S. Lipsitz, and et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study J Clin Oncol 20 2002 1499 1505
29. WHO handbook for reporting results of cancer treatment WHO Offset Publ No 48 Neoplasma 20 1980 37 46
30. B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston, P.M. Schlag, P. Rougier, and et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 2008 1007 1016
31. B. Langer, H. Bleiberg, R. Labianca, and L. Shepherd Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial Proc Am Soc Clin Oncol 21 2002 592
32. M. Rees, D. Elias, F.J. Coimbra, and S.L. Orloff Selection for hepatic resection: expert consensus conference HPB - Off J Int Hepato Pancreato Biliary Assoc 15 2013 104 105
33. D. Zorzi, A. Laurent, T.M. Pawlik, G.Y. Lauwers, J.N. Vauthey, and E.K. Abdalla Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases Br J Surg 94 2007 274 286
34. W.M. Mohammad, G. Martel, R. Mimeault, R.J. Fairfull-Smith, R.C. Auer, and F.K. Balaa Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons HPB 14 2012 291 297
35. S. Bipat, M.S. van Leeuwen, J.N. Ijzermans, P.M. Bossuyt, J.W. Greve, and J. Stoker Imaging and treatment of patients with colorectal liver metastases in the Netherlands: a survey Neth J Med 64 2006 147 151
36. S. Bipat, M.S. van Leeuwen, J.N. Ijzermans, E.F. Comans, A.S. Planting, P.M. Bossuyt, and et al. Evidence-base guideline on management of colorectal liver metastases in the Netherlands Neth J Med 65 2007 5 14
37. O.J. Garden, M. Rees, G.J. Poston, D. Mirza, M. Saunders, J. Ledermann, and et al. Guidelines for resection of colorectal cancer liver metastases Gut 55 Suppl. 3 2006 iii1 iii8
38. B.M. Nordlinger, G.J. Poston, and R.M. Goldberg Reply to J.N. Primrose et al and C.-H. Kohne J Clin Oncol - Off J Am Soc Clin Oncol 33 2015 2408 2409
39. C.H. Kohne Is progression-free survival the right end point in trials of patients with clearly resectable, borderline resectable, and unresectable liver-limited colorectal cancer? J Clin Oncol - Off J Am Soc Clin Oncol 33 2015 2406 2407
40. J.N. Primrose, D. Cunningham, O.J. Garden, T.S. Maughan, S.A. Pugh, L. Stanton, and et al. Cetuximab is contraindicated in the perioperative treatment of colorectal liver metastases J Clin Oncol - Off J Am Soc Clin Oncol 33 2015 2405 2406
41. B. Nordlinger, G.J. Poston, and R.M. Goldberg Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver? J Clin Oncol - Off J Am Soc Clin Oncol 33 2015 241 243
42. K. Hasegawa, M. Oba, and N. Kokudo Cetuximab for resectable colorectal liver metastasis: new EPOC trial Lancet Oncol 15 2014 e305 e306
43. G. Manceau, S. Imbeaud, R. Thiebaut, F. Liebaert, K. Fontaine, F. Rousseau, and et al. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy Clin Cancer Res 20 2014 3338 3347